Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: jeffbas who wrote (3105)	5/31/1999 10:46:00 AM
From: Don Miller	Read Replies (2) \| Respond to of 10280

Bubba8295 of YC brought this bioclinician article to the attention of YC readers. biotechclinician.com

To: jeffbas who wrote (3105)	5/31/1999 11:13:00 AM
From: Don Miller	Read Replies (1) \| Respond to of 10280

Jeffery, Did you catch a name of the companies involved with the CBS release? We have been discussing a Tanox, Genetech, Novartis anti-IgE for some time. Please do a search on that topic here and on the YC board. Seek a recent reply by Richard Harmon of this board about the Tanox drug. Search also my YC authorship (millerd1_airmail_net) and, asthmadoc99, IMARANGERBOY, Pittsull to find further comments. I am an nontechinal that solicited comments from Richarh Harmon here and the above three MDs' with experience in the field. This press release reference tells what Gentech, Novatis and Tanox's drug test produced. quicken.com The improvement described in this press release was quite low. It is also said to be expensive. It requires shots which many do not like. If we are discussing the same drug, I doubt if a .09 or .23 improvement from 0-3 is significant for this allergy sufferer, and shots do not bother me. I have administered my own shots in times past. NBC nightline described this drug in about October or November 98, then again in Feb. 99. Can you confirm what companies and drugs CBS described? Better yet can you find a link to a report that someone with adequate technical knowledge can review and comment.